Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-blinded , Parallel Controlled Trial to Evaluate the Immunogenicity, Safety and Efficacy of A Heterologous Booster Dose With COVID-19 mRNA Vaccines (Bivalent) , in Previously Vaccinated Subjects Against COVID-19 With 2/3 Doses COVID-19 Vaccine Compared to a Booster Dose With mRNA COVID-19 Vaccine（Pfizer Bivalent Vaccine）in Adults.

NCT05911087 is registered in ClinicalTrials.gov with Stemirna Therapeutics as lead sponsor.

NCT NCT05911087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05911087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-blinded , Parallel Controlled Trial to Evaluate the Immunogenicity, Safety and Efficacy of A Heterologous Booster Dose With COVID-19 mRNA Vaccines (Bivalent) , in Previously Vaccinated Subjects Against COVID-19 With 2/3 Doses COVID-19 Vaccine Compared to a Booster Dose With mRNA COVID-19 Vaccine（Pfizer Bivalent Vaccine）in Adults.
Lead sponsor
Stemirna Therapeutics
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 20, 2023
Completion date
February 1, 2024
Enrollment
800 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

immunogenicity, safety